Sep 27, 2021 / 02:00PM GMT
Operator
Greetings, ladies and gentlemen, and welcome to the Incyte's GVHD update conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ms. Christine Chiou, Head of Investor Relations. Thank you. Please go ahead.
Christine Chiou - Incyte Corporation - Head of IR
Thank you, Donna. Good morning, and welcome to Incyte's conference call and webcast to discuss the recent approval of Jakafi in chronic GVHD and this morning's announcement of our collaboration with Syndax Pharmaceuticals.
Speaking on the call today are Herve and Peter Langmuir, our Group Vice President of Development in Oncology Targeted Therapeutics. Barry and Christiana will also participate in the Q&A session.
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements and are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our 10-Q for the quarter ended
Incyte Corp GVHD Update Call: Approval in cGVHD and Syndax Collaboration Transcript
Sep 27, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers